Struggling Encysive brings in Morgan Stanley

Reeling from the third FDA rejection Thelin and the deep budget cuts that followed, Encysive has retained Morgan Stanley to evaluate ways to "maximize shareholder value." Analysts didn't waste time in concluding that the move signaled an effort to find a buyer for the company, which recently terminated 70 percent of its staff following the agency's rejection of its experimental therapy for pulmonary arterial hypertension. Encysive is filing a request for dispute resolution. Meanwhile, former CEO Dr. Bruce D. Given has also resigned from the board, his last position with Encysive.

- check out the Houston Business Journal report on Encysive

Related Articles:
Encysive CEO departs as pink slips fly. Report
Encysive shares sink on third approvable letter. Report
Encysive shares dive after second approvable letter. Report
Encysive takes beating on Thelin delay. Report